Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spesolimab - Boehringer Ingelheim

Next Previous
Drug Profile

Spesolimab - Boehringer Ingelheim

Alternative Names: BI 655130; Spesolimab-sbzo; SPEVIGO

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 36 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Generalised pustular psoriasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Generalised pustular psoriasis
  • Phase III Pyoderma gangrenosum
  • Phase II/III Hidradenitis suppurativa; Netherton Syndrome; Ulcerative colitis
  • Phase II Crohn's disease; Palmoplantar pustulosis
  • Discontinued Atopic dermatitis

Most Recent Events

  • 31 Jul 2025 Boehringer Ingelheim completes the phase-II/III EvasayilTM trial in Netherton-Syndrome (In the elderly, In children, In adolescents, In adults) in USA, United Kingdom, Switzerland, Portugal, Netherlands, Malaysia, Japan, Italy, Israel, Germany, France, China, Bulgaria, Australia (IV) (NCT05856526)
  • 16 Jul 2025 Launched for Generalised pustular psoriasis (In adults, In adolescents, In the elderly) in United Kingdom (IV)
  • 14 Jul 2025 LEO Pharma in-licenses spesolimab from Boehringer Ingelheim

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top